Hydroxyurea

羟基脲

Report date: 2026/04/22 20:01:10
NME

Base Information

Drug NameHydroxyurea
Drug Alias Name羟基尿素HydroxycarbamideSiklosOnco-CarbideMylocel +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRibonucleotide reductase inhibitors
TargetsRibonucleotide reductase
Therapy Area/IndicationsHemochromatosisHemoglobinopathiesThrombocythemia, Essential +[21] 
Global Approved IndicationsAnemia, Sickle CellKidney NeoplasmsHead and Neck Neoplasms +[6] 
Approved Indications in ChinaKidney NeoplasmsHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and Neck +[5] 
Original Approved Country/TerritoryUnited States
Original Approved Date1967/12/07
Country/TerritoryAngolaUnited StatesUganda +[19] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyCaribbean Institute For Health Research (Caihr)Theravia Pharma SAS +[14] 
Inactive CompaniesChildren'S National Research InstituteEunice Kennedy Shriver National Institute Of Child Health And Human DevelopmentInstituto Estadual De Hematologia Arthur De Siqueira Cavalcanti +[13] 
Active IndicationsThrombocythemia, EssentialAnemia, Sickle CellStroke +[9] 
Inactive IndicationsHemochromatosisHemoglobinopathiesbeta-Thalassemia +[12] 

Other Information

ATC CodeL01XX05
Related LinksWikipediaDrugBankKEGG